|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation显示文摘AIM:To evaluate the long-term results of conventional chemoradiotherapy and laparoscopic mesorectal excision in rectal adenocarcinoma patients without adjuvant therapy.METHODS:Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy.Laparoscopic surgery was planned after 5-8 wk.Patients diagnosed with ypT0N0 stage cancer were not treated with adjuvant therapy according to the protocol.Patients with ypT1-2N0 or ypT3-4 or N+were offered 5-fluorouracil-based adjuvant treatment on an individual basis.An external cohort was used as a reference for the findings.RESULTS:One hundred and seventy six patients were treated with induction chemoradiotherapy and 170underwent total mesorectal excision.Cancer staging of ypT0N0 was achieved in 26/170(15.3%)patients.After a median follow-up of 58.3 mo,patients withypT0N0 had five-year disease-free and overall survival rates of 96%(95%CI:77-99)and 100%,respectively.We provide evidence about the natural history of patients with localized rectal cancer achieving a complete response after preoperative chemoradiation.The inherent good prognosis of these patients will have implications for clinical trial design and care of patients.CONCLUSION:Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision might be safe within an experienced multidisciplinary team. | Xabier García-Albéniz Rosa Gallego Ralf Dieter Hofheinz Gloria Fernández-Esparrach Juan Ramón Ayuso-Colella Josep Antoni Bombí Carles Conill Miriam Cuatrecasas Salvadora Delgado Angels Ginés Rosa Miquel Mario Pagés Estela Pineda Verónica Pereira Aarón Sosa Oscar Reig Iván Victoria Luis Feliz Antonio María de Lacy Antoni Castells Iris Burkholder Andreas Hochhaus Joan Maurel | 2014 | World Journal of Gastroenterology2014，20，42： | 5 |
| 2 | 新诊断的慢性髓性白血病患者中尼罗替尼vs伊马替尼的疗效比较显示文摘背景尼罗替尼已证实在新诊断慢性期费城染色体(ph染色体)阳性的慢性髓性白血病(CML)患者中比伊马替尼有更好的疗效。我们在这些患者中比较并评价尼罗替尼与伊马替尼的疗效和安全性。方法在这项随机化、多中心、开放的3期研究中,846名患者来自于过去六个月内被诊断为慢性期ph染色体阳性的CML。我们采用计算机生成的随机数据表、区组分组和以Sokal评分为依据的分层方法将患者按1:1:1比例分别接受尼罗替尼(剂量每天2次,300mg或400mg)、或者伊马替尼(剂量每天1次400mg),以口服的方式予药。主要终点指标是12个月时依据国际评分(BCR-ABLIS)0.1%的BCR-ABL转录水平的重要分子反应率或外周血的实时量化PCR。该项研究在ClinicalTrials.gov注册,项目编号为NCT00471497。结果 24个月时,尼罗替尼组的重要分子反应率显著高于伊马替尼组[201例(71%)尼罗替尼300mg组,187例(67%)尼罗替尼400mg组,124例(44%)伊马替尼组;两种比较P<0.0001]。尼罗替尼组任意时刻完全细胞遗传学反应的比例(定义为BCR-ABLIS水平减少值≤0.0032%)也显著高于伊马替尼组[74例(26%)尼罗替尼300mg组,59例(21%)尼罗替尼400mg组,29例(10%)伊马替尼组;分别P<0.0001和P=0.0004]。加速期或爆发期时,伊马替尼组比尼罗替尼组在克隆进化方面进展更显著(尼罗替尼300mg组2例,尼罗替尼400mg组5例,伊马替尼组17例;分别P=0.0003和P=0.0089)。24个月时,所有组的生存率基本一致,但是两尼罗替尼组的CML相关死亡数比伊马替尼组更少(尼罗替尼300mg组5例,尼罗替尼400mg组3例,伊马替尼组10例)。总的来说,仅有3或4级的非血液病性不良反应在至少2.5%的患者身上表现,分别为头痛[8例(3%)尼罗替尼300mg组,4例(1%)尼罗替尼400mg组,2例(<1%)伊马替尼组]和皮疹[2例(<1%)尼罗替尼300mg组,7例(3%)尼罗替尼400mg组,5例(2%)伊马替尼组]。伊马替尼组的3或4级粒细胞减少症比任意尼罗替尼组更普遍[33例(12%)尼罗替尼300mg组,30例(11%)尼罗替尼400mg组,59例(21%)伊马替尼组]。在研究开展的第二年中报告了另外8例严重不良反应事件(尼罗替尼300mg组4例,尼罗替尼400mg组3例,伊马替尼组1例)。讨论尼罗替尼继续在新诊断慢性期CML患者中表现出更好的疗效。这些结果支持尼罗替尼可作为新诊断患者临床治疗的一线药物。 | 贺洁宇 Kantarjian HM Hochhaus A Saglio G 柳叶刀 | 2012 | 肿瘤药学2012，2，1： | 2 |
| 3 | Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy显示文摘 | Hochhaus A Kantarjian H M Baccarani M | 2007 | BIood2007，109，6： | 1 |
| 4 | AraC - based pharmacotherapy of chronic Mydoid leukemia显示文摘 | Reitex A Hochhaus A Bezger U | 2001 | Expert Opin Pharmacother2001，2，7： | 1 |
| 5 | Dasatinib 显示文摘 | Lindauer M and Hochhaus A | 2010 | Recent Results Cancer Res2010，，： | 1 |
| 6 | Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of ima- tinib therapy 显示文摘 | HOCHHAUS A KANTARJIAN HM BACCARANI M | 2007 | Blood2007，109，6： | 1 |
| 7 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase Ⅲ study (HORIZON Ⅱ ) 显示文摘 | Hoff PM Hochhaus A Pestalozzi BC | 2012 | J Clin Oncol2012，30，29： | 1 |
| 8 | Dasatinib显示文摘 | Lindauer M Hochhaus A | 2010 | Recent Results Cancer Res2010，184，： | 1 |
| 9 | Chronic myelogenous leukemia:molecular and cellular aspects显示文摘 | PASTERNAK G HOCHHAUS A SCHULTHEIS B | 1998 | J Cancer Res Clin Oncol1998，124，2： | 1 |
| 10 | Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia:Low levels of minimal residual disease are associated with continuing remission:German CML Study Group and the UK MRC CML Study Group 显示文摘 | Hochhaus A Reiter A Saussele S | 2000 | Blood2000，95，： | 1 |
| 11 | Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia显示文摘 | Sawyers C Hochhaus A | 2002 | N Engl J Med2002，346，9： | 1 |
| 12 | Reduction of BCR-ABL transqript levels at 6, 12, and 18 months (too) cor- relates with long-term outcomes on imatinib (IM) at 72 Mo: an analysis from the international randomized study of interferon ver- sus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) 显示文摘 | HUGHES TP HOCHHAUS A BRANFORD S | 2008 | Blood2008，112，： | 1 |
| 13 | Chronic myeloid leukaemia显示文摘 | Hehlmann R Hochhaus A Baccarani M | 2007 | Lancet2007，370，： | 1 |
| 14 | Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia显示文摘 | Sawyers C Hochhaus A | 2002 | N Engl J Med2002，346，： | 1 |
| 15 | Chronic myelogenous leukemia: molecular and cellular aspects 显示文摘 | Pasternak G Hochhaus A Schuhheis B | 1998 | J Cancer Res C[in Onco[1998，124，12： | 1 |
| 16 | Favorable long-term follow up results over 6 years for response,survival,and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment显示文摘 | Hochhaus A Druker B Sawyers C | | 0，，： | 1 |
| 17 | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results显示文摘 | Hughes T Deininger M Hochhaus A | 2006 | {H}Blood2006，，1： | 1 |
| 18 | Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment 显示文摘 | Hochhaus A Druker B Sawyers C | 2008 | Blood2008，111，3： | 1 |
| 19 | ENESTnd up- date : continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) 显示文摘 | HUGHES TP HOCHHAUS A SAGLIO G | 2010 | Blood2010，116，： | 1 |
| 20 | BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors:recommendations from an expert panel on behalf of European Leukemia Net显示文摘 | Soverini S Hochhaus A Nicolini FE | 2011 | {H}Blood2011，，05： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员